anti-PSMA antibody-drug conjugate ARX517

{
  "id": "MLC-T-ONC-011048",
  "term": "anti-PSMA antibody-drug conjugate ARX517",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) containing a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against prostate-specific membrane antigen (PSMA) and site-specifically conjugated to two of the microtubule-disrupting toxin amberstatin (AS269), with potential antineoplastic activity. Upon administration of anti-PSMA ADC ARX517, the monoclonal antibody moiety selectively binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells. Upon internalization, amberstatin binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of ARX517, increases payload stability and optimizes its efficacy.",
  "synonyms": [
    "anti-PSMA ADC ARX517",
    "ADC ARX517",
    "anti-PSMA/AS269 ADC ARX517"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-psma-antibody-drug-conjugate-arx517/"
}